

Serious Shortage Protocol (SSP) for Monomil® XL 60mg modified-release tablets – corresponding guidance on endorsement, prescription charges, remuneration and reimbursement plus Q&A.

SSP 059 for Monomil® XL 60mg modified-release tablets

1) Endorsement

The contractor must endorse the prescription form or Electronic Reimbursement Endorsement Message (EREM) as per Clause 9, Part II of the Drug Tariff.

Electronic prescription:

Where SSP endorsement functionality is available on the dispensing system the contractor must select SSP and input the three-digit reference number. The contractor must also select in the system the SSP item that has been supplied.

Example	Endorsement
	Option
<p>Example 1: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Chemydur® 60XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor selects in system Chemydur® 60XL 60mg modified release tablets x 28</p>
<p>Example 2: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Isotard® 60XL modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor selects in system Isotard® 60XL modified release tablets x 28</p>
<p>Example 3: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Monomax® XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor selects in system Monomax® XL 60mg modified release tablets x 28</p>

<p>Example 4: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Tardisc® XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor selects in system Tardisc® XL 60mg modified release tablets x 28</p>
---	--

Non-electronic prescription form:

Example	Endorsement
	Option
<p>Example 1: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Chemydur® 60XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor endorses Chemydur® 60XL 60mg modified release tablets x 28</p>
<p>Example 2: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Isotard® 60XL modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor endorses Isotard® 60XL modified release tablets x 28</p>
<p>Example 3: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Monomax® XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor endorses Monomax® XL 60mg modified release tablets x 28</p>
<p>Example 4: Prescription for Monomil® XL 60mg modified-release tablets x 28 tablets</p> <p>Pharmacy contractor supplies Tardisc® XL 60mg modified release tablets x 28</p>	<p>SSP 059</p> <p>Pharmacy contractor endorses Tardisc® XL 60mg modified release tablets x 28</p>

2) Prescription charges

Pharmacy contractors must take one prescription levy. Only one prescription charge will be applicable for patients who are not exempt from prescription charges.

3) Remuneration

Supply in accordance with this SSP 059 will result in the following fees being paid to the contactor:

- One Single Activity Fee (£1.27)
- One SSP fee (£5.35)

4) Reimbursement

The supplied product in accordance with this SSP 059 will be reimbursed as if it was dispensed against a prescription. In this instance, contractors will be reimbursed the NHS list price for the following products depending on the quantity supplied:

- Chemydur[®] 60XL 60mg modified release tablets
- Relosorb[®] XL 60mg modified release tablets
- Isotard[®] 60XL modified release tablets
- Monomax[®] XL 60mg modified release tablets
- Monosorb[®] XL 60mg modified release tablets
- Tardisc[®] XL 60mg modified release tablets

As of June 2023, a VAT allowance will no longer be paid as products supplied in accordance with an SSP are considered to be VAT zero-rated.

Q&A

Will the SSP apply to cross-border prescriptions?

Yes. Patients from England, Scotland, Wales or Northern Ireland who present their prescriptions for Monomil[®] XL 60mg modified-release tablets are eligible to receive a substituted product under the terms of this SSP 059.

Does the SSP apply to private prescriptions?

Yes. The scope of this SSP 059 applies to valid prescriptions that meets the requirements of the Human Medicine Regulations 2012, so it would cover both NHS and private prescriptions, unless where it stated otherwise on the SSP itself.

Will prescription charges apply under the SSP?

Yes, patients who are not exempt from prescription charges would continue to pay for this as usual. The only circumstance in which patients would not have to pay for a prescription charge is where an SSP specifies a lower quantity to be supplied.

Please note that the SSP for Monomil[®] XL 60mg modified-release tablets does not specify a lower quantity to be supplied, so patients will continue to pay prescription

charges (unless they are already exempt). For more information, please see the above guidance.

What brand would I supply as an alternative under this SSP?

Pharmacies should supply from the medicines in Group 1 in the first instance, supplying from Group 2 where those products in Group 1 are not available. This is based on supply volumes and not clinical interchangeability.

Group 1

- Chemydur[®] 60XL 60mg modified release tablets; or
- Relosorb[®] XL 60mg modified release tablets; or
- Isotard[®] 60XL modified release tablets.

Group 2

- Monomax[®] XL 60mg modified release tablets; or
- Monosorb[®] XL 60mg modified release tablets; or
- Tardisc[®] XL 60mg modified release tablets.

Can pharmacists use their professional judgement to supply an alternative product to patients?

If the pharmacist thinks that an alternative product, other than those listed within the SSP would be suitable for the patient, they should either contact the prescriber to discuss this (with the patient's consent) or direct the patient back to the prescriber.

Should pharmacists provide additional counselling when supplying patients with an alternative product?

The pharmacist will need to discuss with the patient/carer whether they have used any of the alternative brands listed in the SSP before. Where appropriate the patient/carer should be made aware of the change and be warned of possible adverse events that they may experience particularly in the first few days. Please refer to the cautions listed in the SSP, including any relevant actions that need to be taken.

Does the SSP apply to other auto-injector pens?

No, this SSP 059 only applies to prescriptions for Monomil[®] XL 60mg modified-release tablets.